MET Inhibition in Advanced NSCLC: Molecular Testing for METex14 and Emerging Options is organized by Clinical Care Options (CCO), LLC and will be held on May 30, 2020 at Sheraton Grand Chicago, Chicago, Illinois, United States of America.
This program is intended for global medical oncologists, pulmonologists and other healthcare providers who care for patients with NSCLC.
This Conference has been approved for a maximum of 2.0 AMA PRA Category 1 Credits™
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with MET-altered NSCLC.
Upon completion of this activity, participants should be able to:
• Describe the rationale for METex14 as a targetable alteration in NSCLC
• Evaluate the available testing platforms and use of tissue and plasma biopsies to assess METex14 in patients with NSCLC
• Discuss the available clinical evidence for selective MET inhibitors in METex14-altered NSCLC, including an assessment of relative efficacy and central nervous system responses
• Appropriately manage treatment-related adverse events associated with MET targeted agents used in patients with advanced-stage NSCLC
Additional details will be posted as soon as information is available.
|Contact No. :||
|Registration Type||Last Date||Price|
|Course fee||29 May,2020||Free|
Plan Your Travel
Reviews Given by People
Hotels Near Venue
Subscribe to our Newsletterx
Subscribe to our newsletter and receive updates on medical conferences, board review courses and news